BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Leukemia
,
Lymphocyte
,
Autoimmunity
,
Fluoxetine
,
rs2476601
,
DRD2
,
cell-cell adhesion
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
TA-3
(gene)
Summary
General Info
Body Atlas
Most Correlated Tissues
Loading...
Explore Body Atlas Results
Disease Atlas
Most Correlated Diseases
Loading...
Explore Disease Atlas Results
Pharmaco Atlas
Most Correlated Compounds
Loading...
Explore Pharmaco Atlas Results
Knockdown Atlas
Most Correlated Gene Perturbations
Loading...
Explore Knockdown Atlas Results
Curated Studies
Most Correlated Studies
Loading...
Explore Curated Studies Results
Literature
Most Relevant Literature
The endoplasmic reticulum chaperone BiP is a closure-accelerating cochaperone of Grp94.
Cell Surface GRP94 as a Novel Emerging Therapeutic Target for Monoclonal Antibody Cancer Therapy.
Endoplasmin regulates differentiation of tonsil-derived mesenchymal stem cells into chondrocytes thr…
Grp94 Works Upstream of BiP in Protein Remodeling Under Heat Stress.
An internalizing antibody targeting of cell surface GRP94 effectively suppresses tumor angiogenesis …
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
A Phase 3 Study of TAS-205 in Patients With Duchenne Muscular Dystrophy(REACH-DMD)
Sym004 Versus TAS-102 in Patients With mCRC
An Investigation of TAS-119 Monotherapy
Study of TA-NIC to Assess the Efficacy and Safety of the Vaccine as an Aid to Smoking Cessation
Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Canc…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ